03:25 PM EDT, 08/27/2024 (MT Newswires) -- GSK (GSK) shares rose 3.4% in recent Tuesday trading after the Delaware Supreme Court agreed to review a lower court's ruling allowing the plaintiff's expert evidence in litigation over the drugmaker's heartburn medication Zantac, or ranitidine.

The Zantac litigation will continue in parallel with the Delaware Supreme Court review, GSK said.

"The scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer," GSK said in a statement.

Price: 43.98, Change: +1.44, Percent Change: +3.39